Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Race Oncology starts two new trials for RC220 in leukemia and lung cancer, based on new drug insights.

flag Race Oncology has launched two new clinical programs for its drug RC220, targeting acute myeloid leukaemia and EGFR-mutated non-small cell lung cancer, based on new insights into the drug’s mechanism. flag The move aims to address treatment resistance in high-need cancer areas and supports a potential streamlined regulatory path. flag The company is advancing multiple late-stage oncology opportunities simultaneously. flag The announcement was made on November 16, 2025.

5 Articles